As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical …

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in …

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future …

As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive …

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and …

1 day ago · Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said …

Jun 4, 2021 · Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials - Despite being …

As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Adults and children are …

3 days ago · Based on the results, Novo Nordisk is planning further clinical developments for the drug in adults with obesity and overweight. 1. REFERENCES 1. Novo Nordisk successfully …

1 day ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors …